AZN Share Price: Live AstraZeneca Stock Overview
The AZN share price represents AstraZeneca plc, a global biopharmaceutical company listed on the London Stock Exchange (LSE) under the ticker AZN.L. This page provides live AZN stock price, historical performance, peer comparison, and key metrics to help investors make informed decisions.
AstraZeneca (AZN) at a Glance
| Metric | Value |
|---|
| Company | AstraZeneca plc |
| Ticker | AZN (LSE), AZN (NASDAQ ADR) |
| Sector | Pharmaceuticals / Healthcare |
| Headquarters | Cambridge, United Kingdom |
| Founded | 1999 (merger) |
| CEO | Sir Pascal Soriot |
| Market Cap | ~£130 billion+ |
| Employees | 70,000+ |
Live AZN Share Price Comparison
The AZN share price today is compared below against major pharmaceutical and healthcare peers on the LSE:
| Stock | Ticker | Price (GBP) | Change | Market Cap | P/E Ratio |
|---|
| AstraZeneca | AZN.L | Loading... | Loading... | ~£130B | ~18.5 |
| GlaxoSmithKline | GSK.L | Loading... | Loading... | ~£70B | ~12.0 |
| Pfizer | PFE (NYSE) | Loading... | Loading... | ~$160B | ~15.2 |
| Novartis | NOVN (SWX) | Loading... | Loading... | ~CHF 180B | ~17.8 |
| Roche | ROG (SWX) | Loading... | Loading... | ~CHF 240B | ~16.4 |
| Merck (MSD) | MRK (NYSE) | Loading... | Loading... | ~$280B | ~14.9 |
How to Read AZN Share Price Movements
Intraday Trading
- **Open:** First traded price of the day
- **High/Low:** Price range reached during the session
- **Volume:** Number of shares traded
- **Bid/Ask:** Price buyers will pay / sellers will accept
Historical Performance
- **52-week high/low:** Annual trading range
- **YTD return:** Price change since January 1
- **5-year CAGR:** Compound annual growth rate
Key Ratios
- **P/E ratio:** Price-to-earnings (valuation vs profits)
- **EPS:** Earnings per share
- **Dividend yield:** Annual dividend as percentage of share price
- **Beta:** Volatility relative to market (1.0 = market average)
Factors That Affect AZN Share Price
Positive Catalysts
- **Oncology pipeline success:** Tagrisso, Imfinzi, Enhertu approvals
- **Vaccine revenue:** COVID-19 vaccine (Vaxzevria) residual sales
- **M&A activity:** Acquisitions boosting portfolio
- **Emerging markets growth:** China, India, Brazil expansion
- **R&D breakthroughs:** Phase 3 trial successes
Negative Pressures
- **Patent cliffs:** Loss of exclusivity on key drugs
- **Regulatory setbacks:** FDA/EMA rejection or delays
- **Currency headwinds:** Strong GBP reduces dollar earnings
- **Litigation risks:** Patent disputes, product liability
- **Competition:** Biosimilars and rival therapies
AZN vs GSK: Pharma Peer Comparison
| Factor | AstraZeneca (AZN) | GlaxoSmithKline (GSK) |
|---|
| Revenue focus | Oncology, CV, R&I | Pharma, Vx, Consumer |
| Growth profile | High growth (oncology-driven) | Mature, dividend-focused |
| Pipeline strength | Very strong (Enhertu family) | Solid, HIV/Vax focus |
| Dividend yield | ~2.5% | ~4.5% |
| Valuation | Higher P/E (~18) | Lower P/E (~12) |
| Geographic split | US ~45%, Europe ~25% | UK ~25%, US ~35% |
AZN vs Pfizer (PFE): Transatlantic Comparison
| Factor | AZN | Pfizer (PFE) |
|---|
| Key drugs | Tagrisso, Imfinzi, Lynparza | Comirnaty, Eliquis, Prevnar |
| COVID impact | Vaccine used globally | Main revenue driver 2021-22 |
| Pipeline | Strong in ADC (antibody-drug conjugates) | Mix of established and R&D |
| Patent exposure | Patents expiring 2025-2030 | Comirnaty declining sharply |
| Strategy | M&A and partnerships | Cost-cutting, spin-offs |
AZN Share Price Technical Analysis
Moving Averages
- **50-day MA:** Medium-term trend indicator
- **200-day MA:** Long-term trend indicator
- **Golden cross:** 50-day MA crosses above 200-day MA (bullish)
- **Death cross:** 50-day MA crosses below 200-day MA (bearish)
Support and Resistance Levels
| Level Type | Price (GBP) | Description |
|------------|-------------|-------------|
| Resistance 2 | ~£140 | 52-week high area |
| Resistance 1 | ~£125 | Recent swing high |
| Current Price | Live | Market price |
| Support 1 | ~£110 | Recent consolidation floor |
| Support 2 | ~£95 | Major swing low / 200-day MA |
How to Buy AZN Shares
1. Choose a UK Stock Broker
- **Hargreaves Lansdown** (full-service)
- **Interactive Brokers** (global, low-cost)
- **Trading 212** (commission-free)
- **eToro** (social trading, copy portfolios)
- **Saxo Markets** (professional tools)
2. Open and Fund Account
- Complete KYC (passport, proof of address)
- Deposit funds via bank transfer or card
- Allow 1-3 business days for settlement
3. Search for AZN
- Enter ticker: **AZN** or **AZN.L**
- Verify it is **AstraZeneca plc** on LSE
- Double-check ISIN: GB0009895292
4. Place Order
- **Market order:** Buy at current best price
- **Limit order:** Set your desired price
- **Stop-loss:** Automatic sell if price falls
- **Quantity:** Minimum 1 share
5. Monitor and Review
- Track earnings reports quarterly
- Watch pipeline updates and FDA/EMA news
- Set price alerts for key levels
AZN Dividend History
| Year | Dividend Per Share (DPS) | Yield |
|---|
| 2023 | ~£2.20 | ~2.8% |
| 2022 | ~£2.00 | ~2.5% |
| 2021 | ~£1.80 | ~2.2% |
| 2020 | ~£1.60 | ~2.0% |
| 2019 | ~£1.50 | ~1.8% |
AstraZeneca has a growing dividend track record, making it popular with income investors.
AZN Share Price Forecast
| Source | 2026 Target | 2027 Target | Sentiment |
|---|
| Bloomberg Consensus | ~£125-140 | ~£135-155 | Moderate Buy |
| Reuters Analysts | ~£120-135 | ~£130-150 | Hold to Buy |
| Morningstar | ~£130 | ~£140 | Fair Value |
| TipRanks | ~£128 | ~£142 | Buy |
Note: Forecasts are analyst estimates, not guarantees.
Related AZN Tickers and Exchanges
| Ticker | Exchange | Currency | Notes |
|---|
| AZN.L | London Stock Exchange | GBP | Primary listing |
| AZN | NASDAQ (ADR) | USD | American Depositary Receipt |
| AZN.SW | Swiss Exchange | CHF | Cross-listing |
| AZN.DE | XETRA (Germany) | EUR | Cross-listing |
Conclusion
The AZN share price reflects AstraZeneca's position as a global pharma leader with a strong oncology pipeline. Whether you are a retail investor or analyst, tracking AZN.L alongside peers like GSK, Pfizer, and Novartis provides context for valuation and growth expectations.
Use this page's comparison tables to monitor relative performance and stay updated with catalysts that move the stock.